NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
October 26, 2022 07:00 ET
|
NuCana plc
NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination...
NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
September 12, 2022 10:45 ET
|
NuCana plc
NUC-7738 Demonstrates Encouraging Anti-Tumor Activity and a Favorable Safety Profile Across a Variety of Solid Tumors NUC-7738 Monotherapy and Combination with Pembrolizumab to be Investigated in...
NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022
September 12, 2022 08:00 ET
|
NuCana plc
NUC-3373 Demonstrates Promising Anti-Tumor Activity and Safety in Combination with Oxaliplatin (NUFOX) and Irinotecan (NUFIRI) in Heavily Pre-Treated Colorectal Cancer Patients Randomized Study of...
NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022
September 06, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held...
NuCana to Participate in Citi's 17th Annual BioPharma Conference
August 31, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Aug. 31, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings at Citi's 17th Annual BioPharma Conference. ...
NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update
August 17, 2022 16:01 ET
|
NuCana plc
Multiple Data Readouts on Track for the Second Half of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 27, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”)...
German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent
July 11, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the...
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress
June 10, 2022 07:00 ET
|
NuCana plc
NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors ...
NuCana Announces Receipt of NASDAQ Notice
June 03, 2022 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC...